Coulter And Cobra Agree Collaboration

Coulter Pharmaceutical, Inc. and Cobra Therapeutics Ltd, the gene therapy subsidiary of ML Laboratories, have entered into a collaboration to jointly develop and commercialise Cobra’s platform gene expression technology. The technology, known as Ubiquitous Chromatin Opening Elements (UCOEs), is a new class of gene expression elements which induce efficient productivity from genes introduced into target Read more about Coulter And Cobra Agree Collaboration[…]

Coulter Acquires Rights To Novel Technology

Coulter Pharmaceutical, Inc. has entered into a license and research agreement with Yissum, the technology transfer company of Hebrew University, for technology, know-how and worldwide intellectual property rights relating to a novel approach to treating rheumatoid arthritis (RA). This new approach involves reducing RA joint inflammation by targeting the synovial cells responsible for infiltrating and Read more about Coulter Acquires Rights To Novel Technology[…]